USSTOCK.TODAY
Pre-Market
Log in Sign up

Arcutis Biotherapeutics profitability declines due to increased commercial spending despite revenue growth

Earnings Whispers +1 · ·by G4L

ARQT
ARQT Arcutis Biotherapeutics Inc
$26.20 +2.54%
View chart & analysis →
  1. 1Arcutis Biotherapeutics recorded $143.92 million in ZORYVE sales for the third quarter.
  2. 2Arcutis Biotherapeutics' third-quarter ZORYVE sales exceeded consensus by 1.6%.
  3. 3Arcutis Biotherapeutics recorded a third-quarter diluted earnings per share (EPS) of $0.06.

So what's the key point?

Arcutis Biotherapeutics' product sales were 1.6% higher than what experts expected. However, earnings per share were $0.06 because of high spending on selling the products.

Source Earnings Whispers +1 · View original ↗

Related 3-line summaries

Acutis Biotherapeutics to Announce Third Quarter Results After Market Close on November 4 Earnings Whispers · Oct 28Viking Therapeutics and Arcutis Biotherapeutics Await Q4 Catalysts The Motley Fool · Oct 13News Corp Q1 revenue of $2.28 billion beats expectations Proactive +1 · 5d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news